This release includes two upgrades to existing features and one bug fix.
? The first, and biggest, upgrade is the reading experience in the Article view. Various text and paragraph formatting styles are now supported.
? The second upgrade is displaying linked items inside the application instead of opening Safari. Small, but it does make for a better experience.
? The one bug fix was something I wanted to fix for quite a while. Certain feeds – like Medium – did not include their content in a way Stream knew how to parse them. That bug has finally been sent packing.
Nothing major to share. Version 1.0.1 completes the Tip Jar we intended to ship in 1.0.
Why a Tip Jar?
Well, a one time price isn’t sustainable in the long run, even for a one person shop. And subscription fatigue is a thing.
If you’re interested in leaving a tip you can to to settings, scroll to the bottom, tap on Tip Jar, and pick an amount you’d like to tip.
Do I have to leave you a tip to open up features? Nope. Stream will work the same for everyone.
It’s been a few months in the making but RxCalc 1.2 is now available in the App Store.
What’s new? Glad you asked. There are two new features to talk about.
- Support for dosing adjustment using single level vancomycin kinetics.
- The calculations are performed using both patient specific information supplied by the user as well as patient population parameters.
- Literature supported High Dose Extended Interval (HDEI) (aka “once daily” or “pulse”) aminoglycoside dosing.
- Calculations for gentamicin and tobramycin are based on 7mg/kg adjusted body weight.
- Calculations for amikacin are based on 15mg/kg adjusted body weight.
This release was also unique because we finally opened the door to a Beta Tester. Our heartfelt thanks goes out to Robert B. Martin, Pharm.D. Robert provided a critical eye for Jerry’s Pharmacokinetic Calculations and his years of clinical experience were priceless. He’s given us a lot of great feedback we’ll be sure to include in future releases. That’s right, we like to hear from our users!
We hope you enjoy using 1.2 as much as we enjoyed developing it.